Mild to moderate COVID-19 in those aged 40-60 years, elderly, diabetes mellitus and obesity COVID-19, favipiravir, monoclonal antibody, SARS-CoV-2, treatment
Conditions
Interventions
loading dose of oral favipiravir 3600 mg on the initial day, then 1600 mg per day for 4 days (total 5 days)
In obese patients, a loading dose of oral favipiravir 4800 mg on the initial day, then 2000
Treatment,Treatment
Favipiravir treated group,Neutralizing monoclonqal antibodies
Sponsors
Chulabhorn Royal Academy
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Confirmed SARS-COV-2 infected cases by Reverse Transcriptase-Polymerase Chain Reaction or antigen test kit who were treated with outpatients, home isolation 2. Mild to moderate COVID-19 in those aged 40-60, elderly, diabetes mellitus, and obesity 3. Participants accept informed consent 4. body weight more than 40 kilograms 5. Asymptomatic or Symptomatic by present more than or equal to one of the following symptoms: fever, runny nose, sore throat, cough, myalgia, diarrhea, chest discomfort, dyspnea 6. Chest CT severity score 0-14 7. WHO clinical progression scale < 2 8. Age more than 18 years
Exclusion criteria
Exclusion criteria: 1) Respiratory tract symptoms compatible with a bacterial infection 2) Previous receiving anti-SARS-CoV-2 agents more than 24 hours 3) severe COVID-19 or signs and symptoms deterioration at the first visit; respiratory rate more than 26, oxygen saturation less than 95, hypotension defined by SBP less than 90 and DBP less than 60 4.) Need oxygen therapy 5) Pregnancy or breastfeeding 6) Who needs an increased flow of oxygen supplemental in chronic respiratory illnesses 7) Who needs hospitalization for any cause 8) Chest X-ray presents bilateral infiltration or infiltration more than 50 percent or CT chest presence crazy paving pattern or ARDS pattern or CT severity score more than 15 9) Cirrhosis child C or end-stage renal disease who did not receive hemodialysis more than 2 times a week 10) Advanced malignancy (life expectancy less than 3 months) 11) Bedridden 12) who received neutralizing monoclonal antibodies for more than 60 days 13) Casirivimab imdevimab, sotrovimab or favipiravir
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Emergency room visit 28 days visit times | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospitalization 14 and 28 days Number of admission,Oxygen supplemental 28 days Numbers,ICU admission 28 days Numbers,Clinical improvement 5, 14 days Clinical assessment, WHO clinical progression scale,Radiologic change day 5 CT severity score,Virological response 5, 14 days Cycle threshold value ,Mortality 28 days Numbers,Inflammatory marker change 5, 14 days CRP, LDH, presepsin, ESR, D-dimer,Adverse events 28 days Number of adverse events | — |
Countries
Thailand
Contacts
Public ContactTaweegrit Siripongboonsitti
Chulabhorn Royal Academy
Outcome results
None listed